vs
伯乐实验室（BIO）与SPIRE INC（SR）财务数据对比。点击上方公司名可切换其他公司
SPIRE INC的季度营收约是伯乐实验室的1.1倍（$762.2M vs $693.2M），伯乐实验室净利率更高（103.9% vs 12.5%，领先91.4%），SPIRE INC同比增速更快（13.9% vs 3.9%），伯乐实验室自由现金流更多（$119.1M vs $-121.8M），过去两年伯乐实验室的营收复合增速更高（6.5% vs -17.8%）
美国伯乐实验室是深耕生命科学研究与临床诊断领域的专业技术产品开发商及制造商，1952年由加州大学伯克利分校校友施瓦茨夫妇在伯克利创立，总部位于加州赫拉克勒斯，业务网络覆盖全球。
Spire Inc是总部位于美国密苏里州圣路易斯的区域公用事业控股公司，核心业务为受监管的天然气供应服务，同时布局非监管类业务拓展商业机会。旗下主要子公司Laclede Gas Company是密苏里州最大的天然气分销公用事业企业，为圣路易斯市及密苏里州东部10个县的约63.1万户住宅、商业及工业客户提供服务。
BIO vs SR — 直观对比
营收规模更大
SR
是对方的1.1倍
$693.2M
营收增速更快
SR
高出10.1%
3.9%
净利率更高
BIO
高出91.4%
12.5%
自由现金流更多
BIO
多$240.9M
$-121.8M
两年增速更快
BIO
近两年复合增速
-17.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $693.2M | $762.2M |
| 净利润 | $720.0M | $95.0M |
| 毛利率 | 49.8% | 55.1% |
| 营业利润率 | -17.2% | 22.8% |
| 净利率 | 103.9% | 12.5% |
| 营收同比 | 3.9% | 13.9% |
| 净利润同比 | 200.6% | 16.9% |
| 每股收益（稀释后） | $26.59 | $1.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOSR
| Q4 25 | $693.2M | $762.2M | ||
| Q3 25 | $653.0M | $334.1M | ||
| Q2 25 | $651.6M | $421.9M | ||
| Q1 25 | $585.4M | $1.1B | ||
| Q4 24 | $667.5M | $669.1M | ||
| Q3 24 | $649.7M | $293.8M | ||
| Q2 24 | $638.5M | $414.1M | ||
| Q1 24 | $610.8M | $1.1B |
净利润BIOSR
| Q4 25 | $720.0M | $95.0M | ||
| Q3 25 | $-341.9M | $-39.8M | ||
| Q2 25 | $317.8M | $20.9M | ||
| Q1 25 | $64.0M | $209.3M | ||
| Q4 24 | $-715.8M | $81.3M | ||
| Q3 24 | $653.2M | $-25.9M | ||
| Q2 24 | $-2.2B | $-12.6M | ||
| Q1 24 | $383.9M | $204.3M |
毛利率BIOSR
| Q4 25 | 49.8% | 55.1% | ||
| Q3 25 | 52.6% | — | ||
| Q2 25 | 53.0% | — | ||
| Q1 25 | 52.3% | — | ||
| Q4 24 | 51.2% | 55.6% | ||
| Q3 24 | 54.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 53.4% | — |
营业利润率BIOSR
| Q4 25 | -17.2% | 22.8% | ||
| Q3 25 | 10.0% | -0.1% | ||
| Q2 25 | 11.8% | 16.4% | ||
| Q1 25 | 4.0% | 29.1% | ||
| Q4 24 | 8.7% | 22.2% | ||
| Q3 24 | 9.9% | 6.7% | ||
| Q2 24 | 15.9% | 7.4% | ||
| Q1 24 | 7.3% | 26.5% |
净利率BIOSR
| Q4 25 | 103.9% | 12.5% | ||
| Q3 25 | -52.4% | -11.9% | ||
| Q2 25 | 48.8% | 5.0% | ||
| Q1 25 | 10.9% | 19.9% | ||
| Q4 24 | -107.2% | 12.2% | ||
| Q3 24 | 100.5% | -8.8% | ||
| Q2 24 | -339.2% | -3.0% | ||
| Q1 24 | 62.9% | 18.1% |
每股收益（稀释后）BIOSR
| Q4 25 | $26.59 | $1.54 | ||
| Q3 25 | $-12.70 | $-0.77 | ||
| Q2 25 | $11.67 | $0.29 | ||
| Q1 25 | $2.29 | $3.51 | ||
| Q4 24 | $-25.89 | $1.34 | ||
| Q3 24 | $23.34 | $-0.63 | ||
| Q2 24 | $-76.26 | $-0.28 | ||
| Q1 24 | $13.45 | $3.58 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $4.1M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $7.5B | $3.4B |
| 总资产 | $10.6B | $11.9B |
| 负债/权益比越低杠杆越低 | 0.16× | — |
8季度趋势，按日历期对齐
现金及短期投资BIOSR
| Q4 25 | $1.5B | $4.1M | ||
| Q3 25 | $1.4B | $5.7M | ||
| Q2 25 | $1.4B | $13.1M | ||
| Q1 25 | $1.7B | $15.2M | ||
| Q4 24 | $1.7B | $11.5M | ||
| Q3 24 | $1.6B | $4.5M | ||
| Q2 24 | $1.6B | $7.4M | ||
| Q1 24 | $1.6B | $25.6M |
总债务BIOSR
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BIOSR
| Q4 25 | $7.5B | $3.4B | ||
| Q3 25 | $6.7B | $3.4B | ||
| Q2 25 | $7.1B | $3.5B | ||
| Q1 25 | $6.7B | $3.5B | ||
| Q4 24 | $6.6B | $3.3B | ||
| Q3 24 | $7.5B | $3.2B | ||
| Q2 24 | $6.8B | $3.3B | ||
| Q1 24 | $9.1B | $3.4B |
总资产BIOSR
| Q4 25 | $10.6B | $11.9B | ||
| Q3 25 | $9.7B | $11.6B | ||
| Q2 25 | $10.2B | $11.4B | ||
| Q1 25 | $9.5B | $11.3B | ||
| Q4 24 | $9.4B | $11.3B | ||
| Q3 24 | $10.6B | $10.9B | ||
| Q2 24 | $9.7B | $10.7B | ||
| Q1 24 | $12.6B | $10.7B |
负债/权益比BIOSR
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.9M | $81.0M |
| 自由现金流经营现金流 - 资本支出 | $119.1M | $-121.8M |
| 自由现金流率自由现金流/营收 | 17.2% | -16.0% |
| 资本支出强度资本支出/营收 | 6.6% | 26.6% |
| 现金转化率经营现金流/净利润 | 0.23× | 0.85× |
| 过去12个月自由现金流最近4个季度 | $374.6M | $-286.7M |
8季度趋势，按日历期对齐
经营现金流BIOSR
| Q4 25 | $164.9M | $81.0M | ||
| Q3 25 | $120.9M | $-4.9M | ||
| Q2 25 | $116.5M | $129.1M | ||
| Q1 25 | $129.9M | $372.7M | ||
| Q4 24 | $124.2M | $81.1M | ||
| Q3 24 | $163.6M | $82.9M | ||
| Q2 24 | $97.6M | $270.1M | ||
| Q1 24 | $69.8M | $489.4M |
自由现金流BIOSR
| Q4 25 | $119.1M | $-121.8M | ||
| Q3 25 | $89.2M | $-227.6M | ||
| Q2 25 | $70.8M | $-91.4M | ||
| Q1 25 | $95.5M | $154.1M | ||
| Q4 24 | $81.2M | $-179.5M | ||
| Q3 24 | $123.4M | $-146.9M | ||
| Q2 24 | $55.4M | $47.9M | ||
| Q1 24 | $29.6M | $306.6M |
自由现金流率BIOSR
| Q4 25 | 17.2% | -16.0% | ||
| Q3 25 | 13.7% | -68.1% | ||
| Q2 25 | 10.9% | -21.7% | ||
| Q1 25 | 16.3% | 14.7% | ||
| Q4 24 | 12.2% | -26.8% | ||
| Q3 24 | 19.0% | -50.0% | ||
| Q2 24 | 8.7% | 11.6% | ||
| Q1 24 | 4.8% | 27.2% |
资本支出强度BIOSR
| Q4 25 | 6.6% | 26.6% | ||
| Q3 25 | 4.9% | 66.7% | ||
| Q2 25 | 7.0% | 52.3% | ||
| Q1 25 | 5.9% | 20.8% | ||
| Q4 24 | 6.4% | 38.9% | ||
| Q3 24 | 6.2% | 78.2% | ||
| Q2 24 | 6.6% | 53.7% | ||
| Q1 24 | 6.6% | 16.2% |
现金转化率BIOSR
| Q4 25 | 0.23× | 0.85× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.37× | 6.18× | ||
| Q1 25 | 2.03× | 1.78× | ||
| Q4 24 | — | 1.00× | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.18× | 2.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
SR
| Residential | $474.9M | 62% |
| Commercial And Industrial | $148.4M | 19% |
| Gas Marketing | $41.1M | 5% |
| Midstream | $39.0M | 5% |
| Transportation | $37.1M | 5% |
| Offsystem And Other Inventive | $19.7M | 3% |
| Other Customer Revenue | $4.6M | 1% |
